Relara Partners LLC
Scope of Services
Last updated: September 2026
This page states plainly what Relara Partners LLC does and does not do. It is here because part of our work involves analyzing the drug development programs of publicly traded companies, and we want no ambiguity about what that analysis is.
What we do
Relara Partners LLC provides regulatory strategy consulting for drug development. Our work includes:
- Developing global regulatory strategy and submission plans for clinical-stage programs
- Leading Health Authority interactions, briefing packages, and marketing applications
- Technical regulatory analysis of drug development programs, including approval pathway assessment, benchmarking against precedent in the indication, and identification of regulatory risk
- Regulatory due diligence supporting mergers, acquisitions, licensing, and partnership evaluations
- Evaluation and improvement of artificial intelligence models on regulatory and drug development tasks
The object of our analysis is the drug development program, not the security. We assess whether a development plan is likely to support approval, what the agency is likely to require, and how a program compares to precedent. We do not assess what a company is worth or what its shares should trade at.
What we do not do
Relara Partners LLC is not an investment adviser, broker-dealer, research analyst, or fiduciary, and is not registered as any of those with the Securities and Exchange Commission or any state securities regulator. We do not:
- Provide investment advice, or recommend that anyone buy, sell, or hold any security
- Produce valuations, price targets, ratings, or earnings estimates
- Manage money, exercise discretion over any account, or receive compensation tied to any trading outcome
- Advise on the merits of an investment, a financing, or a transaction as an investment
Nothing we produce should be construed as a recommendation with respect to any security. Clients are responsible for their own decisions and should consult their own financial, legal, and tax advisers.
Sources of information
Analysis concerning publicly traded companies is based solely on publicly available information — including company press releases and presentations, clinical trial registries such as ClinicalTrials.gov, published Health Authority guidance and precedent, peer-reviewed literature, and public regulatory filings.
Where a transaction party provides access to a data room under a non-disclosure agreement, information received is used solely for that engagement. It is not used in work for any other client, and it is not used for any other purpose.
We do not otherwise seek or accept material non-public information.
How we are paid
Our fees are fixed, hourly, or retainer-based, agreed in writing before work begins. We do not accept success fees, carried interest, equity in funds, or any compensation contingent on a trading, financing, or transaction outcome.
Conflicts
We maintain a written restricted list of companies whose confidential information we hold, and we decline engagements that would create a conflict with an existing client. If a conflict arises during an engagement, we will tell you.
Engagement terms
Every engagement is governed by a signed engagement letter setting out scope, deliverables, fees, confidentiality, and term. Where this page and an engagement letter differ, the engagement letter governs.